

2 0 1 6
9th PARIS
HEPATITIS
CONFERENCE

11 & 12 January 2016

PARIS - Palais des Congrès

**International Conference on the Management
of Patients with Viral Hepatitis**

Organised by Pr Patrick Marcellin

Organising Committee

Emilie Estrabaud, Michelle Martinot-Peignoux, Monelle Muntlak
Hôpital Beaujon, APHP - INSERM CRI - Université Paris-Diderot

Scientific Committee

Marc Bourlière, Massimo Colombo, Rafael Esteban,
Graham Foster, Michael Fried, Michael Manns

www.aphc.info



Follow us on Twitter: @PHC_off #PHC2016

PRELIMINARY
PROGRAMME



Dear Colleagues,

We are pleased to announce that the 9th Paris Hepatitis Conference (PHC) will take place on January 11 and 12, 2016.

As usual, the meeting will provide state of the art information on the management of patients with hepatitis B and hepatitis C by leading edge international experts who will present the most recent data and their opinion on the clinical applications.

Thanks to the outstanding progress made in the treatment of hepatitis C with the new combinations of DAAs, 95% of patients with HCV can now potentially be cured including formerly « difficult to treat » patients (cirrhotics, coinfection with HIV, transplantation...). These combinations are well tolerated and very effective in all genotypes with shorter treatment (almost 100% SVR after 12 weeks of treatment and a significant portion of the population responding after just 8 weeks). Indeed, these advances raise the issue of how to facilitate access to treatment in more patients with the realistic objective of eradicating hepatitis C.

Eradication of HCV is now a dream shared by experts all over the world. To reach this goal a joint strategy is necessary including different regions and countries. To further our investigation in this direction we decided to create an international scientific committee for the PHC 2016. I would like to warmly thank my colleagues Marc Bourlière (France), Massimo Colombo (Italy), Rafael Esteban (Spain), Graham Foster (UK), Michael Fried (USA), and Michael Manns (Germany) who have accepted to participate in this committee.

As discussed during the 8th PHC, recent treatments are not yet available in most countries with large populations of HCV patients. First or second-generation triple therapies have just been introduced in many countries. Therefore, optimal strategies that take into account the severity of the liver disease must be defined in relation to available resources and drugs.

The PHC 2016 will also spend a full day addressing important issues related to hepatitis B. We will discuss the long-term efficacy and tolerance in patients receiving the most potent available antivirals. Recent studies with up to 8 years of treatment report favourable outcomes with the regression of fibrosis and a decrease in the incidence of HCC in treated patients without viral resistance. We will also address the role of quantification of HBsAg which seems to be a new tool to assess the severity of the disease and the response to therapy. Finally the optimal management of difficult populations will be extensively discussed: co-infections, cirrhosis...

As in previous PHCs, interactive discussions and specific lunch workshops have been organized to review the management of real life patients. Indeed, the ultimate goal of the PHC 2016 is to review the most current knowledge and discuss their therapeutic applications with the most experienced experts to provide optimal therapy and the best chance of cure to as many patients as possible, worldwide.

I look forward to welcoming you to Paris,

Professor Patrick Marcellin
President of the 9th Paris Hepatitis Conference

HEPATITIS C

08.30 Introduction: Treatment of hepatitis C: Access to eradication!

Patrick Marcellin (France)

08.40 - 09.00 State of the art lecture

Chairman: Tarik Asselah (France)

- The influence of therapy on the burden of hepatitis C

Michael Fried (USA)

09.00 - 10.00 Who to treat?

Chairmen: Antonio Craxi (Italy) and Stanislas Pol (France)

- 09.00 ■ Why do I treat my patients with mild hepatitis?

Antonio Craxi (Italy)

- 09:15 ■ Why don't I treat my patients with mild hepatitis?

Christophe Hézode (France)

- 09.30 ■ Is the benefit to treat patients with cirrhosis proven?

Savino Bruno (Italy)

- 09:45 ■ Round table discussion

☕ 10.00 - 10.20 Coffee break

10.20 - 11.05 How to optimize therapy?

Chairmen: Marc Bourlière (France) and Jake Liang (USA)

- 10.20 ■ Is it useful to detect resistance associated variants?

Stefan Zeuzem (Germany)

- 10.35 ■ Individual optimization of therapy (shorten therapy)

Graham Foster (UK)

- 10.50 ■ Round table discussion

11.05 - 12.30 How to improve access to therapy? Around the World table

NORTH & WEST

Chairman: Massimo Colombo (Italy)

Speakers: Nezam Afdhal (USA), Victor de Ledinghen (France), Rafael Esteban (Spain), Graham Foster (UK), Michael Manns (Germany)

SOUTH & EAST

Chairmen: Robert Flisiak (Poland) and Adrian Gadano (Argentina)

Speakers: Raymundo Parana (Brazil), Vasily Isakov (Russia), Mihai Voiculescu (Romania)

12.30 - 14.30 Lunch Workshops

14.30 - 15.35 Special populations

Chairpersons: Maria Buti (Spain) and François Durand (France)

- 14:30 ■ Patients with chronic kidney diseases

Stanislas Pol (France)

- 14:45 ■ DAAs and transplanted patients

Didier Samuel (France)

- 15:00 ■ HIV-HCV co-infected patients

Mark Sulkowski (USA)

- 15:15 ■ Round table discussion

☕ 15:35 - 16:05 Coffee break

16.05 - 16.55 New therapeutic strategies

Chairmen: Michael Manns (Germany) and Shiv Sarin (India)

- 16.05 ■ How to improve the therapeutic strategies ?

Tarik Asselah (France)

- 16.20 ■ How to provide the best treat with what is available?

David Nelson (USA)

- 16.35 ■ Round table discussion

16.55 - 17.40 How to optimize the strategy against HCV?

Chairmen: Peter Ferenci (Austria) and Eugene Schiff (USA)

- 16.55 ■ Universal screening?

Mitchell Shiffman (USA)

- 17.10 ■ Follow-up of patients with SVR

Lawrence Serfaty (France)

- 17:25 ■ Round table discussion

17.40 - 17.50 Take home messages

17.50 - 18.00 Conclusion

Patrick Marcellin (France)

19.30 Congress dinner

PROGRAMME OF THE LUNCH WORKSHOPS

The list of the speakers will be shortly announced.

January 11th from 12:30 to 14:30

- 01- Future therapies for HBV and HDV
- 02- First line therapy of hepatitis B: Interferon or analogues ?
- 03- Clinical applications of HBsAg quantification
- 04- Staging of fibrosis: liver biopsy or indirect markers?
- 05- Treatment of HCV cirrhosis and transplanted patients
- 06- HIV-HCV coinfection
- 07- Traitement du VHB : interféron ou analogues ? (French speaking lunch workshop)
- 08- Futurs traitements pour le VHB et le VHD (French speaking lunch workshop)

January 12th from 12:15 to 14:15

- 09- How to optimize treatment in G4 patients?
- 10- HCV eradication with DAAs?
- 11- How to manage HCV relapsers and non-responders to PEG IFN + RBV therapy?
- 12- How to optimize treatment in G3 patients?
- 13- Relevance of the assessment of resistance associated variants in HCV before DAAs treatment
- 14- Management and treatment of NASH
- 15- Traitements des patients VHC rechuteurs et non répondeurs (French speaking lunch workshop)
- 16- Cirrhose et transplantation hépatique (French speaking lunch workshop)

HEPATITIS B

08.30 Introduction: Hepatitis B, the come back? *Patrick Marcellin (France)*

08.40 - 10.00 **What's new in hepatitis B?**

Chairmen: Laurent Castera (France) and Fabien Zoulim (France)

08.40 ■ Clinical relevance of HBV cccDNA *Fabien Zoulim (France)*

08.55 ■ Virological markers for the management of patients *Michelle Martinot-Peignoux (France)*

09.10 ■ New therapeutic perspectives? *Jia-Horng Kao (Taiwan)*

09.30 ■ Round table discussion

☕ 10.00 - 10.30 Coffee break

10.30 - 11.45 **Optimal therapy of chronic hepatitis B**

Chairmen: Adrian Gadano (Argentina) and Ji Dong Jia (China)

10.30 ■ Do I treat my immunotolerant patients? *Georgios Papatheodoridis (Greece)*

10.45 ■ Prognosis and management of inactive carriers *Pietro Lampertico (Italy)*

11.00 ■ Which pregnant women to treat? *Ji Dong Jia (China)*

11.15 ■ Round table discussion

11.45 - 12.15 **State of the art lecture**

Chairman: Marc Bourlière (France)

■ Hepatitis E: the neglected one *Jean-Marie Péron (France)*

12.15 - 14.15 **Lunch Workshops**

14.15 - 14.45 **State of the art lecture and award**

Chairman: Patrick Marcellin (France)

■ The adventure of Delta *Mario Rizzetto (Italy)*

14.45 - 16.00 **End-stage liver disease is a multifaceted condition**

Chairmen: Adrian Di Bisceglie (USA) and Richard Moreau (France)

14.45 ■ Management of uninfected and infected ascites in cirrhosis *Pere Gines (Spain)*

15.00 ■ Iron and the liver *Antonello Pietrangelo (Italy)*

15.15 ■ Treatment of hepatocellular carcinoma: beyond international guidelines *Massimo Colombo (Italy)*

15.30 ■ Round table discussion

16.00 **Take home messages**

16.10 **Conclusion**

Patrick Marcellin (France)

16.20 Closing session

2016 9th PARIS HEPATITIS CONFERENCE

PALAIS DES CONGRÈS CONGRESS CENTER



INFORMATION

CONFERENCE DATES

The 9th Paris Hepatitis Conference will be held in Paris, France, from Monday 11^h to Tuesday 12th January 2016.

CONFERENCE VENUE

The congress will be held at the Paris Congress Centre "Palais des Congrès" located at Porte Maillot, a few minutes walking distance from the Champs Elysées.

Address:

2, place de la Porte Maillot
75017 Paris – France

Metro and RER station:

"Porte Maillot"

OFFICIAL LANGUAGE

The official language of the conference is English.

REGISTRATION

On-line registration only via the web site:
www.aphc.info

Registration includes access to the scientific sessions, lunches and coffee breaks.

A congress dinner is organised on Monday 11th January 2016 (limited seats).

ACCOMMODATION

C'accommodation has negotiated special congress rates. Hotels have been selected for their quality, price, and location. Reservations have to be made through C'accommodation by 30th November 2015 at the latest and are subject to availability. To book accommodation, please go to the web site: www.aphc.info

CME CONTINUOUS MEDICAL EDUCATION ACCREDITATION

An application has been made to the EACCME for CME accreditation of this event.

CONGRESS ADMINISTRATIVE SECRETARIAT

Quadrature Santé / PHC 2016
43 rue des Tilleuls
92100 Boulogne-Billancourt

Phone: +33 1 41 10 46 60

Fax: +33 1 41 10 46 69

Contact: contact@phc-congress.com

www.aphc.info